In a limited cohort of specimens originating from 16 NSCLC patients, most of them featuring strong EGFR phosphorylation, we could identify a sample (patient 10) with a very high (0.99) OAPS score for EGFR inhibition by gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.